Ligand Reports First Quarter 2018 Financial Results

Go back to Ligand Reports First Quarter 2018 Financial Results

Ligand Pharma (LGND) Tops Q1 EPS by 40c

May 8, 2018 4:45 PM EDT

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.55, $0.40 better than the analyst estimate of $1.15. Revenue for the quarter came in at $56.2 million versus the consensus estimate of $43.02 million.

GUIDANCE:

Ligand Pharma sees FY2018 EPS of $4.85, versus the consensus of $4.67.

Ligand affirms... More